Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
Precision Perspectives: Navigating Advancements in HR+ / HER2 Negative Breast Cancer Care : Episode 6
Evaluating the Impact of Metastatic Breast Cancer on Patients
An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.
EP: 1.Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer
EP: 2.Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer
EP: 3.CDK4/6 Inhibitors as First-Line Options in Metastatic Breast Cancer
EP: 4.Treatment Algorithms for Early and Metastatic Breast Cancer
EP: 5.NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer
Now Viewing
EP: 6.Evaluating the Impact of Metastatic Breast Cancer on Patients
EP: 7.Highlighting the Available CDK4/6 Inhibitors
EP: 8.Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC
EP: 9.Applying NCCN Guidelines in the Treatment of mBC
EP: 10.CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC
EP: 11.Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events
EP: 12.Navigating Financial Barriers: Cost-Saving Strategies and Patient Assistance Programs
EP: 13.Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer
Related Videos
Related Content
